CheckMate 743 shows that dual immunotherapy, nivolumab + ipilimumab, improves overall survival for patients with treatment-naïve mesothelioma DENVER, Aug. 08, 2020 (GLOBE NEWSWIRE) -- The combination of first-line nivolumab and.
SAN DIEGO, June 09, 2021 (GLOBE NEWSLETTER) -- eFFECTOR Therapeutics, Inc. , a leader in the development of selective translational regulation inhibitors (STRIs) for the treatment of cancer, today announced.
Severance Hospital researchers have identified key factors that can predict patients' responses to anticancer treatments by analyzing bile duct cancer genes from patients with a poor prognosis. Bile duct cancer,.
A new test is being tried to improve early diagnosis of lung cancer, which could increase patients' chances of survival.Over the next three years, a total of 10,000 people in.
Researchers may have found a biomarker for lung cancer that will soon allow health care providers to detect the disease while it is still in stage 1.Share on PinterestDoctors may.
AstraZeneca has announced a series of encouraging research results, a new drug approval and a new major appointment.A Phase III Study Has Shown AstraZeneca and MSDs Lynparza (olaparib) reduced the.